Celgene Co. (CELG) Given Consensus Recommendation of “Buy” by Analysts

Shares of Celgene Co. (NASDAQ:CELG) have earned an average recommendation of “Buy” from the thirty-five brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and nineteen have assigned a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $130.82.

CELG has been the subject of several recent analyst reports. Vetr upgraded Celgene from a “hold” rating to a “buy” rating and set a $146.58 price target for the company in a research note on Friday, October 6th. Royal Bank of Canada reiterated a “buy” rating and set a $173.00 price target on shares of Celgene in a research note on Thursday, October 5th. Cantor Fitzgerald reiterated a “buy” rating and set a $162.00 price target on shares of Celgene in a research note on Tuesday, September 26th. Robert W. Baird reiterated a “buy” rating and set a $162.00 price target on shares of Celgene in a research note on Thursday, September 21st. Finally, Jefferies Group reiterated a “buy” rating and set a $160.00 price target on shares of Celgene in a research note on Friday, September 15th.

Several hedge funds have recently made changes to their positions in the business. Capital Counsel LLC NY lifted its position in shares of Celgene by 0.4% in the 2nd quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock worth $214,000 after acquiring an additional 6 shares during the period. Fort Pitt Capital Group LLC lifted its position in shares of Celgene by 0.6% in the 2nd quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock worth $250,000 after acquiring an additional 11 shares during the period. Savant Capital LLC lifted its position in shares of Celgene by 0.9% in the 2nd quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock worth $305,000 after acquiring an additional 20 shares during the period. TCI Wealth Advisors Inc. lifted its position in shares of Celgene by 0.9% in the 2nd quarter. TCI Wealth Advisors Inc. now owns 3,043 shares of the biopharmaceutical company’s stock worth $395,000 after acquiring an additional 26 shares during the period. Finally, Granite Investment Advisors LLC lifted its position in shares of Celgene by 1.1% in the 2nd quarter. Granite Investment Advisors LLC now owns 2,579 shares of the biopharmaceutical company’s stock worth $352,000 after acquiring an additional 29 shares during the period. Institutional investors own 79.74% of the company’s stock.

Shares of Celgene (NASDAQ:CELG) traded up $1.58 during mid-day trading on Friday, reaching $106.16. The company’s stock had a trading volume of 5,585,107 shares, compared to its average volume of 7,643,650. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. Celgene has a 12 month low of $94.55 and a 12 month high of $147.17. The firm has a market cap of $83,690.00, a price-to-earnings ratio of 25.04, a P/E/G ratio of 0.68 and a beta of 1.77.

Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. Celgene had a return on equity of 43.32% and a net margin of 30.06%. The business’s revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.58 EPS. sell-side analysts forecast that Celgene will post 6.68 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Celgene Co. (CELG) Given Consensus Recommendation of “Buy” by Analysts” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/04/celgene-co-celg-given-consensus-recommendation-of-buy-by-analysts.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply